5AM-Affiliated Entities Report Large CAMP Purchase on Form 4
Rhea-AI Filing Summary
Camp4 Therapeutics insider acquisition: Multiple 5AM-affiliated entities and Kush Parmar reported purchases and beneficial holdings of Camp4 Therapeutics (CAMP) common stock. On 09/11/2025 a purchase transaction (code P) was reported for 2,941,176 shares at $1.53 per share. The filing lists beneficial holdings following the transaction: 2,941,176 shares held by 5AM Ventures VII, L.P., 2,625,145 shares by 5AM Ventures VI, L.P., and 302,770 shares by 5AM Opportunities II, L.P. The reporting parties disclose indirect ownership through related general partner entities and state shared voting and investment power; the statements include disclaimers limiting beneficial ownership to pecuniary interest.
Positive
- Large non-derivative acquisition disclosed: 2,941,176 shares purchased at $1.53 per share on 09/11/2025
- Clear ownership mapping: Filing details indirect holdings across 5AM Ventures VII, 5AM Ventures VI, and 5AM Opportunities II with explicit disclaimers
- Proper signatures: Managing member Kush Parmar and related entities signed the Form 4, indicating procedural compliance
Negative
- None.
Insights
TL;DR: Significant insider purchase by 5AM-affiliated funds, showing increased stake but no new derivatives disclosed.
The Form 4 reports a single non-derivative acquisition on 09/11/2025: 2,941,176 shares purchased at $1.53 each by entities affiliated with 5AM Ventures VII. The filing clarifies ownership is held indirectly across multiple 5AM vehicles and includes standard disclaimers. For investors, this is a material ownership increase by affiliated venture funds but the filing contains no earnings, financing, or derivative activities to contextualize the purchase.
TL;DR: Related-party disclosures are complete; managing members assert shared voting power with standard disclaimers.
The disclosure identifies 5AM Partners entities and named individuals (Dr. Kush Parmar and Andrew J. Schwab) as managing members with shared voting and investment power. Signatures from the managing member accompany the filing. The explanatory footnotes properly describe the chain of ownership and disclaimers, consistent with Section 16 reporting practices; no departures from standard governance disclosure conventions are evident in the text provided.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 2,941,176 | $1.53 | $4.50M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The shares are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. The shares are directly held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the sole general partner of Opportunities II. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP and Dr. Parmar disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
